Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb;4(1):205-11.
doi: 10.2147/tcrm.s1603.

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma

Ranjit K Goudar  1
Affiliations

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma

Ranjit K Goudar. Ther Clin Risk Manag. 2008 Feb.

Abstract

Malignant pleural mesothelioma is a resistant form of lung cancer, and its incidence continues to rise in Europe and Australia. Until recently, chemotherapy had not been shown to be effective in the treatment of this slowly progressive disease. In 2004, the combination of pemetrexed and cisplatin was shown to induce high response rates in MPM. This article reviews the published literature describing the development and testing of this therapeutic combination in mesothelioma, and examines in detail the key phase III clinical trial that led to the approval of pemetrexed by the US FDA. Ongoing research will further define the role of pemetrexed plus cisplatin in the treatment of MPM.

Keywords: cisplatin; malignant pleural mesothelioma; mesothelioma; pemetrexed.

PubMed Disclaimer

References

    1. Adjei AA, Calvert AH, Hanauske AR, et al. Pemetrexed (ALIMTA), a novel multitargeted antifolate agent, is active alone and in combination in thoracic tumors. Lung Cancer. 2000;29:38–9.
    1. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma:a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38:111–21. - PubMed
    1. Boyer M, Jassem J, Al ALE. Symptoms and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer. 2003;41:S19.
    1. British Thoracic Society. Statement on malignant mesothelioma in the United Kingdom. Thorax. 2001;56:250–65. - PMC - PubMed
    1. Budde LS, Hanna NH. Pemetrexed (Alimta.:improving outcomes in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2004;4:361–8. - PubMed